The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Atmaca, Akin ^a   Werner, Dominique ^a   Pauligk, Claudia ^a   Steinmetz, Kristina ^a   Wirtz, Ralph ^b   Altmannsberger, Hans Michael ^a   Jäger, Elke ^a   Al Batran, Salah Eddin ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b STRATIFYER Molecular Pathology GmbH   (Germany)

Author keywords

EGFR; Gastric cancer; Immunohistochemistry; Prognostic; Survival

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; MESSENGER RNA; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STOMACH CANCER;

DISEASE-FREE SURVIVAL; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868703338     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-524     Document Type: Article

References (25)

1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, . V325 Study group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006, 24:4991-4997. 10.1200/JCO.2006.06.8429, 17075117, V325 Study group.
2. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E. Biweekly fluorouracil, leucovorin, Oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Onc 2008, 19:1882-1887.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and Oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46. 10.1056/NEJMoa073149, 18172173.
4. Bang Y, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-Oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X, 20728210.
5. García I, Vizoso F, Martín A, Sanz L, Abdel-Lah O, Raigoso P, García-Muñiz JL. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003, 10:234-241. 10.1245/ASO.2003.05.010, 12679307.
6. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007, 31:1458-1468. 10.1007/s00268-007-9016-4, 17516110.
7. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, Busch R, Hermannstädter C, Nährig J, Becker KF, Becker I, Höfler H, Fend F, Luber B. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 2004, 17:579-587. 10.1038/modpathol.3800085, 15073595.
8. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008, 15:69-79. 10.1245/s10434-007-9596-0, 17896140.
9. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008, 52:738-746. 10.1111/j.1365-2559.2008.03021.x, 18397279.
10. Matsubara J, Yamada Y, Nakajima TE, Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008, 74:76-83.
11. Terashima M, Ochiai A, Kitada K, Ichikawa W, Kurahashi I, Sakuramoto S, Fukagawa T, Sano T, Imamura H, Sasako M. Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study [abstract]. J Clin Oncol 2011, 29(4013):259.
12. Song HS, Do YR, Kim IH, Sohn SS, Kwon KY. Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat 2004, 36:240-245. 10.4143/crt.2004.36.4.240, 2843891, 20368841.
13. Kim JS, Kim MA, Kim TM, Lee SH, Kim DW, Im SA, Kim TY, Kim WH, Yang HK, Heo DS, Bang YJ, Lee KU, Choe KJ, Kim NK. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br J Cancer 2009, 10:732-738.
14. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either Oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008, 26(9):1435-1442. 10.1200/JCO.2007.13.9378, 18349393.
15. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008, 19:1882-1887. 10.1093/annonc/mdn403, 18669868.
16. Al-Batran S, Homann N, Hartmann JT, et al. 5-Fluorouracil, leucovorin, and Oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2010, 28(suppl):15s. Abstr 4013.
17. Al-Batran S, Hofheinz R, Homann N, et al. Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 2011, 29(Suppl):273. Abstr 4070.
18. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T, Sunamori M, Handa M, Kondo T, Sasano H. Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab 2003, 88:2309-2317. 10.1210/jc.2002-021353, 12727990.
19. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, . IALT Bio investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991. 10.1056/NEJMoa060570, 16957145, IALT Bio investigators.
20. Bohmann K, Hennig G, Rogel U, Poremba C, Mueller BM, Fritz P, Stoerkel S, Schaefer KL. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. Clin Chem 2009, 55:1719-1727. 10.1373/clinchem.2008.122572, 19617290.
21. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 2008, 26:832-839.
22. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Prognosis of metastatic gastric cancer by HER2 status: a European and US international collaborative analysis. Ann Oncol 2012, [in press].
23. Linos K, Sheehan CE, Ross JS. Correlation of HER2 and PTEN status with clinical outcome in esophageal (E), gastric (G), and gastroesophageal junction (GEJ) adenocarcinomas (ACs). J Clin Oncol 2011, 29(suppl):15s. Abstr 4066.
24. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Onco 2011, 8:492-503.
25. Waddell TS, Chau I, Barbachano Y, Gonzalez De Castro D, Wotherspoon A, Saffery C, Middleton GW, Wadsley J, Ferry DR, Mansoor W, Crosby TD, Coxon FY, Smith D, Waters JS, Iveson T, Falk S, Slater S, Okines AF, Cunningham D. A randomized multicenter trial of Epirubicin, Oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) [abstract]. J Clin Oncol 2012, 30(LBA4000):239.